SCHEMBL10210779

SCHEMBL10210779

CN1CCCC2(CC(c3ccncc3)=NO2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
USP2 O75604 3/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 2/20 0.37
TDP1 Q9NUW8 2/20 0.36
PKM P14618 1/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
HTR2B P41595 2/20 0.34
SSTR5 P35346 2/20 0.33
HIF1A Q16665 1/20 0.33
GAA P10253 1/20 0.32
ROCK2 O75116 3/20 0.32
ROCK1 Q13464 3/20 0.32
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10210780 0.88 CHRNB4 (0.55) CHRNB4CHRNA3TSHRSSTR5
SCHEMBL10210781 0.85 CRBN (0.45) CHRNB4CHRNA3CYP2D6CYP2C9TSHR
SCHEMBL10168575 0.83 CHRNB4 (0.40) CHRNB4CHRNA3USP2CYP2D6HSD17B10
SCHEMBL10211559 0.79 CHRNB4 (0.41) CHRNB4CHRNA3CYP2D6CYP2C9PKM
SCHEMBL10210782 0.78 CHRNB4 (0.38) CHRNB4CHRNA3USP2CYP2D6CYP2C9
SCHEMBL3084584 0.72 CYP2C9 (0.49) CHRNB4CHRNA3USP2CYP2C9TSHR
SCHEMBL10168605 0.71 CHRNB4 (0.52) CHRNB4CHRNA3CYP2D6HTR2BSSTR5
SCHEMBL3089912 0.71 TDP1 (0.40) CHRNB4CHRNA3USP2CYP2D6CYP2C9
SCHEMBL938967 0.70 CHRNB4 (0.37) CHRNB4CHRNA3USP2CYP2D6CYP2C9
SCHEMBL14534188 0.70 CHRNB4 (0.53) CHRNB4CHRNA3HTR2BSSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT CHRNB4 2625/4885CHRNA3 2203/4885USP2 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.